Targeted Therapy and Immunotherapy Use in NSCLC

10/28/2018

baum At the 23rd Annual Perspectives in Thoracic Oncology meeting held in New York, Joshua M. Bauml, MD, Assistant Professor of Medicine at the Hospital of the University of Pennsylvania, Philadelphia, told attendees about the varying treatment options available for patients with non–small-cell lung cancer (NSCLC).

In this 3-part video series, Dr Bauml talks about targeted therapy and the use of genetic markers in NSCLC, and discusses the current and future landscape of immunotherapy for NSCLC.

Check out all 3 parts of the series with Dr Bauml below!

---

Genetic Markers in NSCLC

Dr Bauml discusses genetic markers found in NSCLC and how to use them to target therapy for individual patients.

Watch Here

Barriers to Using Targeted Therapy in NSCLC

Dr Bauml discusses the role of targeted therapy in NSCLC and some of the barriers to using this treatment approach.

Watch Here

Immunotherapy for NSCLC

Dr Bauml, discusses the role of immunotherapy in the current treatment landscape of NSCLC.

Watch Here

Recent News

News

Pirtobrutinib Demonstrates Promising Efficacy, Safety Among Patients With B-Cell Malignancies With Richter Transformation

09/06/2024

Amber Denham ;

Pirtobrutinib treatment shows encouraging safety and activity among patients with relapsed/refractory B-cell malignancies who experience Richter transformation, according to a subgroup analysis from the phase 1/2 BRUIN study.

Pirtobrutinib treatment shows...

09/06/2024

Oncology

Conference Coverage

Sacituzumab Govetican Shows Promise for Second-Line Extensive-Stage Small Cell Lung Cancer

09/05/2024

Allison Casey ;

According to updated results from the TROPiCS-03 trial, sacituzumab govetican showed promising antitumor activity among patients with both platinum-resistant and platinum-sensitive extensive-stage small cell lung cancer in the second-line...

According to updated results...

09/05/2024

Oncology

News

Optimal Trastuzumab Deruxtecan Dose for Patients With HER2-Positive Advanced Colorectal Cancer

09/05/2024

Stephanie Holland ;

According to results from the phase 2 DESTINY-CRC02 trial, 5.4 mg/kg of trastuzumab deruxtecan is preferable to 6.4 mg/kg among patients with HER2-positive metastatic colorectal cancer.

According to results from the...

09/05/2024

Oncology

News

Tarlatamab Sustained Clinical Benefit Among Previously Treated Patients With Small Cell Lung Cancer

09/04/2024

Stephanie Holland ;

According to extended follow-up results from the DeLLphi-300 trial, tarlatamab sustained clinical benefit among previously treated patients with small cell lung cancer.

According to extended follow-up...

09/04/2024

Oncology

News

Autologous Hematopoietic Cell Transplantation Demonstrates Improved Outcomes Over CAR-T Among Patients With Relapsed LBCL Who Achieve Complete Remission

08/30/2024

Amber Denham ;

According to results from a retrospective study, among patients with relapsed large B-cell lymphoma who achieve a complete remission, treatment with autologous hematopoietic cell transplantation is associated with improved clinical outcomes...

According to results from a...

08/30/2024

Oncology

News

Belzutifan Improved Survival, Response Among Patients With Advanced Clear-Cell Renal Cell Carcinoma

08/30/2024

Stephanie Holland ;

According to results from the phase 3 LITESPARK-005 trial, belzutifan significantly improved progression-free survival and overall response among patients with advanced clear-cell renal cell carcinoma, previously treated with immune...

According to results from the...

08/30/2024

Oncology

News

Revumenib Demonstrates Clinical Benefit Among Patients With High-Risk, R/R KMT2Ar Acute Leukemia

08/30/2024

Amber Denham ;

According to phase 1/2 results from the AUGMENT study, revumenib, an inhibitor of the menin-lysine methyltransferase 2A interaction, demonstrated high remission rates with a predictable safety profile among patients with relapsed/refractory...

According to phase 1/2 results...

08/30/2024

Oncology

News

Sovleplenib Demonstrates Clinically Meaningful Response Among Patients With Chronic Primary Immune Thrombocytopenia

08/29/2024

Amber Denham ;

Sovleplenib, a novel spleen tyrosine kinase inhibitor, demonstrated a clinically meaningful, sustained platelet response among patients with chronic primary immune thrombocytopenia, according to results from a phase 3 study.

Sovleplenib, a novel spleen...

08/29/2024

Oncology

News

Lymph Node Dissection Improved Overall Survival Among Patients With Stage 3 Endometrial Cancer

08/29/2024

Stephanie Holland ;

According to results from a univariable and multivariable analysis, undergoing lymph node dissection at the time of hysterectomy improved overall survival among patients with stage 3 endometrial cancer.

According to results from a...

08/29/2024

Oncology

News

Hearing Loss Among Pediatric Patients with Neurofibromatosis Type 1

08/29/2024

Allison Casey ;

According to a review of audiometric data, the rate of hearing loss among patients with neurofibromatosis type 1 (NF1) compared to the general population was higher than expected.

According to a review of...

08/29/2024

Oncology